×
S&P 500   3,862.49 (+0.81%)
DOW   31,174.41 (+0.67%)
QQQ   288.13 (+0.41%)
AAPL   142.70 (+0.81%)
MSFT   265.77 (+1.11%)
META   168.34 (+0.09%)
GOOGL   2,277.03 (+0.52%)
AMZN   114.19 (+0.61%)
TSLA   689.77 (-1.35%)
NVDA   150.94 (+0.87%)
NIO   20.62 (-7.03%)
BABA   117.58 (-2.12%)
AMD   74.85 (-0.47%)
MU   57.44 (+1.25%)
CGC   2.64 (-2.58%)
T   21.08 (-0.43%)
GE   61.59 (-0.71%)
F   11.09 (-0.98%)
DIS   95.98 (-1.23%)
AMC   12.43 (-2.74%)
PFE   52.20 (+1.08%)
PYPL   73.11 (-1.73%)
NFLX   183.75 (-1.15%)
S&P 500   3,862.49 (+0.81%)
DOW   31,174.41 (+0.67%)
QQQ   288.13 (+0.41%)
AAPL   142.70 (+0.81%)
MSFT   265.77 (+1.11%)
META   168.34 (+0.09%)
GOOGL   2,277.03 (+0.52%)
AMZN   114.19 (+0.61%)
TSLA   689.77 (-1.35%)
NVDA   150.94 (+0.87%)
NIO   20.62 (-7.03%)
BABA   117.58 (-2.12%)
AMD   74.85 (-0.47%)
MU   57.44 (+1.25%)
CGC   2.64 (-2.58%)
T   21.08 (-0.43%)
GE   61.59 (-0.71%)
F   11.09 (-0.98%)
DIS   95.98 (-1.23%)
AMC   12.43 (-2.74%)
PFE   52.20 (+1.08%)
PYPL   73.11 (-1.73%)
NFLX   183.75 (-1.15%)
S&P 500   3,862.49 (+0.81%)
DOW   31,174.41 (+0.67%)
QQQ   288.13 (+0.41%)
AAPL   142.70 (+0.81%)
MSFT   265.77 (+1.11%)
META   168.34 (+0.09%)
GOOGL   2,277.03 (+0.52%)
AMZN   114.19 (+0.61%)
TSLA   689.77 (-1.35%)
NVDA   150.94 (+0.87%)
NIO   20.62 (-7.03%)
BABA   117.58 (-2.12%)
AMD   74.85 (-0.47%)
MU   57.44 (+1.25%)
CGC   2.64 (-2.58%)
T   21.08 (-0.43%)
GE   61.59 (-0.71%)
F   11.09 (-0.98%)
DIS   95.98 (-1.23%)
AMC   12.43 (-2.74%)
PFE   52.20 (+1.08%)
PYPL   73.11 (-1.73%)
NFLX   183.75 (-1.15%)
S&P 500   3,862.49 (+0.81%)
DOW   31,174.41 (+0.67%)
QQQ   288.13 (+0.41%)
AAPL   142.70 (+0.81%)
MSFT   265.77 (+1.11%)
META   168.34 (+0.09%)
GOOGL   2,277.03 (+0.52%)
AMZN   114.19 (+0.61%)
TSLA   689.77 (-1.35%)
NVDA   150.94 (+0.87%)
NIO   20.62 (-7.03%)
BABA   117.58 (-2.12%)
AMD   74.85 (-0.47%)
MU   57.44 (+1.25%)
CGC   2.64 (-2.58%)
T   21.08 (-0.43%)
GE   61.59 (-0.71%)
F   11.09 (-0.98%)
DIS   95.98 (-1.23%)
AMC   12.43 (-2.74%)
PFE   52.20 (+1.08%)
PYPL   73.11 (-1.73%)
NFLX   183.75 (-1.15%)
NASDAQ:AMTX

Aemetis Stock Forecast, Price & News

$4.52
-0.27 (-5.64%)
(As of 07/6/2022 02:30 PM ET)
Add
Compare
Today's Range
$4.46
$4.89
50-Day Range
$4.79
$10.46
52-Week Range
$4.45
$23.33
Volume
17,394 shs
Average Volume
885,143 shs
Market Capitalization
$156.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50

Aemetis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
561.4% Upside
$29.50 Price Target
Short Interest
Bearish
40.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Aemetis in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.78) to ($0.47) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.76 out of 5 stars

Oils/Energy Sector

188th out of 390 stocks

Industrial Organic Chemicals Industry

17th out of 25 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive AMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aemetis and its competitors with MarketBeat's FREE daily newsletter.

Aemetis logo

About Aemetis (NASDAQ:AMTX) Stock

Aemetis, Inc. operates as a renewable natural gas and renewable fuels company in North America and India. It operates through three segments: California Ethanol, Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products. It sells biodiesel primarily to government oil marketing companies, transport companies, resellers, distributors, and private refiners through its own sales force and independent sales agents, as well as to brokers who resell the product to end-users. The company also produces and sells ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. In addition, it produces dairy biogas; produces and sells high-grade alcohol and various feed products, as well as hand sanitizers; and researches and develops conversion technologies using waste feedstocks to produce biofuels and biochemicals. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.

AMTX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:AMTX
Employees
158
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/06/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$29.50
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+552.7%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
5 Analysts

Profitability

Net Income
$-47,150,000.00
Pretax Margin
-21.45%

Debt

Sales & Book Value

Annual Sales
$211.95 million
Book Value
($3.62) per share

Miscellaneous

Free Float
29,621,000
Market Cap
$156.30 million
Optionable
Not Optionable
Beta
0.40














Aemetis Frequently Asked Questions

Should I buy or sell Aemetis stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aemetis stock.
View analyst ratings for Aemetis
or view top-rated stocks.

What is Aemetis' stock price forecast for 2022?

5 equities research analysts have issued 1-year price objectives for Aemetis' shares. Their AMTX stock forecasts range from $25.00 to $33.00. On average, they anticipate Aemetis' stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 555.6% from the stock's current price.
View analysts' price targets for Aemetis
or view top-rated stocks among Wall Street analysts.

How has Aemetis' stock performed in 2022?

Aemetis' stock was trading at $12.30 at the start of the year. Since then, AMTX shares have decreased by 63.4% and is now trading at $4.50.
View the best growth stocks for 2022 here
.

When is Aemetis' next earnings date?

Aemetis is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Aemetis
.

How were Aemetis' earnings last quarter?

Aemetis, Inc. (NASDAQ:AMTX) posted its earnings results on Thursday, May, 12th. The specialty chemicals company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.17. The specialty chemicals company had revenue of $52.05 million for the quarter, compared to the consensus estimate of $55.52 million.
View Aemetis' earnings history
.

Who are Aemetis' key executives?

Aemetis' management team includes the following people:

What other stocks do shareholders of Aemetis own?

What is Aemetis' stock symbol?

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

How do I buy shares of Aemetis?

Shares of AMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aemetis' stock price today?

One share of AMTX stock can currently be purchased for approximately $4.50.

How much money does Aemetis make?

Aemetis (NASDAQ:AMTX) has a market capitalization of $155.61 million and generates $211.95 million in revenue each year. The specialty chemicals company earns $-47,150,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How many employees does Aemetis have?

Aemetis employs 158 workers across the globe.

How can I contact Aemetis?

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The official website for Aemetis is www.aemetis.com. The specialty chemicals company can be reached via phone at (408) 213-0940, via email at investors@aemetis.com, or via fax at 408-252-8044.

This page (NASDAQ:AMTX) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.